Clinical Trials Browser

Approved for marketing × INDUSTRY × Pancreatic Neoplasms × Clear all

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing

BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary